Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Recruiting 3Not yet recruiting 3Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1

Interventions

pembrolizumab 550Specimen Handling 462Carboplatin 441Magnetic Resonance Spectroscopy 429Cyclophosphamide 412Cisplatin 398Radiotherapy 313Gemcitabine 310Bevacizumab 306Paclitaxel 294Biopsy 259Drug Therapy 248Capecitabine 241Oxaliplatin 239fludarabine 238Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 202Dexamethasone 186Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 145durvalumab 143Leucovorin 138atezolizumab 137toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Duloxetine Hydrochloride × Clear all
NCT04560673 2025-12-31

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

M.D. Anderson Cancer Center

Phase 2 Recruiting
380 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04970121 2024-09-25

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy

The First Affiliated Hospital of Bengbu Medical University

Phase 2 Recruiting
100 enrolled

Pain

NCT06551051 2024-09-19

ADC-induced Neurotoxicity Treated With Duloxetine

Fudan University

Phase 2 Recruiting
37 enrolled

Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡